Related Experiment Video
Updated: Jan 11, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Advances in Prostate Cancer Treatment: Exploring Molecular Targets and New Strategies in Castration-Resistant Disease
Praveen Gopi1, Muhammed Ishfaq1, Shopon K Das1
1Department of Urology, Mersey and West Lancashire Teaching Hospitals NHS Trust, Prescot, GBR.
Abstract:
Castration-resistant prostate cancer represents a major clinical challenge, emerging when tumors progress despite standard androgen deprivation therapy. The development of resistance is complex, driven by diverse molecular mechanisms, including androgen receptor (AR) gene amplification and splice variants, as well as AR-independent bypass pathways such as the PI3K/AKT/mTOR and immune checkpoint pathways. These mechanisms involve alternative growth factor signaling, neuroendocrine differentiation, and genetic or epigenetic alterations. This review synthesizes recent advances in understanding these resistance pathways and highlights emerging therapeutic strategies designed to overcome them. Key developments include next-generation AR pathway inhibitors, such as darolutamide, with improved safety profiles; PARP inhibitors for patients with DNA repair gene mutations; and PSMA-targeted radioligand therapy. The therapeutic landscape is also expanding to include novel targets such as the heat shock response, with HSF1 inhibitors like NXP800 in clinical trials for treatment-refractory disease. By targeting this molecular heterogeneity, ongoing research aims to deliver more effective, personalized treatments to improve survival and quality of life for men with advanced prostate cancer.
Insights
Castration-resistant prostate cancer progresses due to complex molecular changes. New therapies target these resistance pathways, including androgen receptor (AR) inhibitors and novel agents, to improve patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Castration-resistant prostate cancer (CRPC) is a significant clinical challenge.
- Tumor progression occurs despite androgen deprivation therapy (ADT).
- Resistance mechanisms are diverse, involving AR pathway alterations and bypass signaling.
Purpose of the Study:
- To review recent advances in understanding CRPC resistance mechanisms.
- To highlight emerging therapeutic strategies targeting these pathways.
- To discuss novel treatment approaches for advanced prostate cancer.
Main Methods:
- Literature review of recent scientific publications.
- Synthesis of data on molecular mechanisms of resistance.
- Analysis of emerging therapeutic strategies and clinical trials.
Main Results:
- Identified key resistance mechanisms: AR amplification, splice variants, PI3K/AKT/mTOR, immune checkpoints, neuroendocrine differentiation.
- Highlighted novel therapies: next-generation AR inhibitors (e.g., darolutamide), PARP inhibitors, PSMA-targeted radioligand therapy.
- Discussed emerging targets like heat shock response (HSF1 inhibitors).
Conclusions:
- Targeting molecular heterogeneity is crucial for effective CRPC treatment.
- Personalized treatment strategies are essential for improving survival and quality of life.
- Ongoing research offers hope for more effective therapies for advanced prostate cancer.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers